{
  "name" : "twin.sci-hub.se_6195_ef1aaa53d124ee1f9c43ae75b1005905_masoudipour2017.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "A Targeted Drug Delivery System Based on Dopamine Functionalized Nano Graphene Oxide",
    "authors" : [ "Elham Masoudipour", "Soheila Kashanian", "Nasim Maleki" ],
    "emails" : [ "kashanian_s@yahoo.com" ],
    "sections" : [ {
      "heading" : null,
      "text" : "Accepted Manuscript\nResearch paper\nA Targeted Drug Delivery System Based on Dopamine Functionalized Nano Graphene Oxide\nElham Masoudipour, Soheila Kashanian, Nasim Maleki\nPII: S0009-2614(16)30968-X DOI: http://dx.doi.org/10.1016/j.cplett.2016.12.019 Reference: CPLETT 34386\nTo appear in: Chemical Physics Letters\nReceived Date: 28 September 2016 Revised Date: 30 November 2016 Accepted Date: 8 December 2016\nPlease cite this article as: E. Masoudipour, S. Kashanian, N. Maleki, A Targeted Drug Delivery System Based on Dopamine Functionalized Nano Graphene Oxide, Chemical Physics Letters (2016), doi: http://dx.doi.org/10.1016/ j.cplett.2016.12.019\nThis is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain."
    }, {
      "heading" : "A Targeted Drug Delivery System Based on Dopamine Functionalized Nano",
      "text" : "Graphene Oxide\nElham Masoudipour a , Soheila Kashanian b, c , Nasim Maleki d\na Department of Biology, Faculty of Science, Razi University, Kermanshah, Iran\nb Faculty of Chemistry, Sensor and Biosensor Research Center (SBRC) & Nanoscience and Nanotechnology Research Center (NNRC), Razi University, Kermanshah, Iran\nc Nano Drug Delivery Research Center, Kermanshah University of Medical sciences, Kermanshah, Iran\nd Department of Applied Chemistry, Faculty of Chemistry, Razi University, Kermanshah, Iran\n*Corresponding author, E-mail: kashanian_s@yahoo.com\nPhone: +98 9183311450\nFax: +98 8314274559"
    }, {
      "heading" : "Abstract",
      "text" : "The cellular targeting property of a biocompatible drug delivery system can widely increase the therapeutic effect against various diseases. Here, we report a dopamine conjugated nano graphene oxide (DA-nGO) carrier for cellular delivery of the anticancer drug, Methotrexate (MTX) into DA receptor positive human breast adenocarcinoma cell line. The material was characterized using scanning electron microscopy, atomic force microscopy, Fourier transform infrared spectroscopy and UV–vis spectroscopy. Furthermore, the antineoplastic action of MTX loaded DA-nGO against DA receptor positive and negative cell lines were explored. The results presented in this article demonstrated that the application of DA functionalized GO as a targeting drug carrier can improve the drug delivery efficacy for DA receptor positive cancer cell lines and promise future designing of carrier conjugates based on it.\nKeywords: Dopamine; Functionalized graphene oxide; Methotrexate; Targeted drug delivery."
    }, {
      "heading" : "Abbreviations",
      "text" : "nGO, Nano Graphene oxide; DA, Dopamine; MTX, Methotrexate; EPR, Enhanced permeation and retention; EDC, N-(3-dimethylaminopropyl-N'-ethylcarbodiimide) hydrochloride; NHS, NHydroxysuccinimide; FT-IR, Fourier transform infrared; AFM, Atomic force microscopy; FESEM, Field emission scanning electron microscopy; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl tetrazolium bromide; DLC, Drug loading content; DLE, Drug loading efficiency; DMEM, Dulbecco's modified eagle medium; FBS, Fetal bovine serum; SD, Standard Deviation."
    }, {
      "heading" : "1. Introduction",
      "text" : "Targeted nano drug delivery as an encouraging strategy can improve the bio-availability, biocompatibility and safety of therapeutic agents [1]. This may help to solve the problems associated with cancer treatment to reduce the dose-limiting cytotoxicity of the drug and also can enable the drug to bypass the drug resistance [2, 3]. Nanocarriers can increase the intracellular concentration of drugs in cancer cells using both passive and active targeting strategies, while preventing toxicity in normal cells [4]. Passive targeting is generally mentioned as the enhanced permeation and retention (EPR) effect, while “active targeting” is used to explain specific interactions between the drug carrier and the target cells. Nanocarriers can be conjugated with different targeting ligands to bind to cancer specific receptors and then enter the cell via receptor-mediated endocytosis and thereby bypassing drug resistance mechanisms [4, 5].\nTo date, several ligand-receptor systems have been studied for targeted drug delivery such as lectin receptors, Fc receptors, complement receptors, interleukin receptors, lipoprotein receptors, transferrin receptors and receptors expressed on tumor cells [6]. Dopamine (DA) receptors are examples of these receptors that are overexpressed in some cancer cells, such as human colon adenocarcinoma cells and breast cancer cells [7, 8]. It recently has been exerted for delivery of some anti-cancer drugs. DA is a monoamine catecholamine neurotransmitter, which operates via its D1 and D2 class of receptors and has a significant function in central nervous system of brain [9]. Therefore, DA functionalized nano carriers can be employed for specific targeting of cancer cells that have DA receptors. Das and Jana investigated that DA functionalized polymeric nanoparticle can selectively deliver anticancer drugs curcumin, camptothecin and doxorubicin to human colon adenocarcinoma cells and expected to be an alternative drug delivery carrier for in vitro and in vivo applications [8]. Chakroborty et al. used animal models of human colon and\nprostate cancers, to indicate that DA can increase blood flow and improve the efficiency of anticancer drug delivery to the tumors [10].\nIn biomedical fields, graphene oxide (GO) and its derivatives are attracting great attention to develop nanocarriers for biomedical applications, biological imaging and so on. Due to one-atom thickness and two-dimensional plane, GO can provide a large specific surface area for the immobilization of a large number of drugs [11]. The surface functionalization of graphene sheets are important for their applications. It improves their aqueous dispersibility, reduce aggregation of nanosheets, decrease the toxicity, and increase its selectivity [12]. Zhao and Liu investigated a carboxylated GO conjugated folate-terminated PEG (CG–PEG–FA) nanocarrier which demonstrated lasting dispersibility in PBS media, excellent cytocompatibility, high drug-loading efficiency, and perfect targeting to folate receptor [3].\nIn the present work, DA was conjugated to nGO via amide bonding to design a targeted nanocarrier for delivery of an anti-cancer drug, methotrexate (MTX). MTX is a folic acid analog used as a chemotherapeutic agent, widely applied in the treatment of a wide range of cancers, rheumatoid arthritis, and other diseases [13]. The MTX loaded nanocarrier was characterized using Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and atomic force microscopy (AFM). A kinetics study of the drug release from GO in the PBS media has been investigated. Furthermore, the antineoplastic action of the drug loaded nanocarrier against DA receptor positive and negative cell lines was explored."
    }, {
      "heading" : "2. Materials and methods",
      "text" : "2.1.Materials\nThe materials obtained from the indicated sources and used in the present study without further purification are as follows: graphite flakes, N-(3-dimethylaminopropyl-N'-ethylcarbodiimide) hydrochloride (EDC) and N-Hydroxysuccinimide (NHS) were obtained from Sigma-Aldrich (St Louis, MO); DA, Chloroacetic acid and NaOH were purchased from Merck (Darmstadt, Germany); and methotrexate was obtained from INTAS (India). The MCF7 and HEK-293 cell lines were obtained from Cellular and Molecular Research Center of Kermanshah University of Medical Science and Shiraz University of Medical Science, respectively."
    }, {
      "heading" : "2.2. Methods",
      "text" : ""
    }, {
      "heading" : "2.2.1. Preparation of nGO",
      "text" : "GO was synthesized following the Modified Hummer’s method [14]. Graphite flakes (1 g) and sodium nitrate (0.75 g) were put in an Erlenmeyer flask in an ice bath to keep the temperature below 5 °C. Then, the concentrated sulfuric acid (34 mL) and KMnO4 (4.5 g) were added with stirring and the resulting mixture was maintained stirring for 5 days. Next, diluted H2SO4 (50 mL, 5 wt %) was added to the reaction mixture and heated at 90°C with stirring. Afterwards, H2O2 solution (2.7 mL 30 wt %) was added to the reaction mixture and stirred for 2 h at room temperature. The acquired GO sheets were washed with H2SO4 (3 wt %), H2O2 (0.5 wt %), H2O2 (0.5 wt %), and HCl (3 wt %) and centrifuged. Finally, the washing was continued with distilled water until the pH of the solution reached to neutral and then the sheets were dried. Next, 10 mg of the acquired GO was dispersed in 1 mL of distilled water by ultrasonication to produce the homogeneous suspension of nGO."
    }, {
      "heading" : "2.2.2. DA functionalization on nGO",
      "text" : "DA (2 mg), EDC (0.2 mg), and NHS (0.1 mg) were dissolved in 5 mL of PBS, pH 7.4. The pH was adjusted to 6.0 by addition of 0.2 M HCl. The mixture was allowed to react for 30 min and then was added drop wise to the nGO suspension (1 mL, 10 mg/mL). The pH was adjusted to 8.0 with 0.2 M NaOH. The reaction was allowed to take place at room temperature for 48 h. Following the DA conjugation, the product was purified by washing with distilled water and centrifugation at 14,000 rpm for 15 min at 4°C.Then, the precipitate was lyophilized for 24 h."
    }, {
      "heading" : "2.2.3. Synthesis of carboxylated DA-nGO",
      "text" : "First, NaOH (1.2 g) and Chloroacetic acid (1.2 g) were added to the aqueous dispersion of DAnGO (2 mg/mL) and sonicated for 3 h to alter –OH and epoxide groups to –COOH groups by the attachment of –CH2COOH linker [15]. Afterwards, the diluted HCl was added to make the solution neutral. Finally, the acquired carboxylated DA-nGO was purified by centrifugation and washing 3 times with the distilled water and was dried under vacuum.\nDrug loading on DA-nGO carrier MTX (3 mg) was added to 2 mL of aqueous dispersion of carboxylated DA-nGO (5 mg/mL) at pH 4.7 and the mixture was stirred at 500 rpm for 1 h at 37 °C. Following the drug absorption on the surface of nanocarrier, the product was purified by washing with distilled water and centrifugation at 14,000 rpm for 15 min at 4 °C. Then, the precipitate was lyophilized for 24 h. The supernatant that contained the unbounded drugs was maintained for calculation of the drug-loading content by monitoring the drug concentration using a UV spectrophotometer at 302 nm. To study the effect of presence of DA in uptake of nanocarriers, a MTX loaded nGO was synthesized using the same method while the same amount of nGO was used instead of carboxylated DA-nGO for MTX loaded nGO synthesis."
    }, {
      "heading" : "2.2.4. Characterization",
      "text" : "The FT-IR spectra were recorded on a FT-IR Bruker-Tensor 27 spectrometer in the region of 400–4000 cm −1 utilizing KBr pellets. The solid samples were completely blended and gathered over 24 scans with a spectral resolution of 4 cm -1 . The morphology of samples was characterized using Field Emission Scanning Electron Microscope (FE-SEM Hitachi S-4160) at an accelerating voltage of 30 kV. After preparation of samples on aluminum tabs, they were coated with gold. Subsequently, the samples were scanned and the photomicrographs were acquired. Measurement of hydrodynamic diameter and polydispersity index (PDI) of the nanocarriers was accomplished using photon correlation spectroscopy (Nano ZS4700, Malvern Instruments, Worcestershire, UK). Therefore ll formulations were diluted by deionized water to eliminate the effect of viscosity caused by the ingredients. The data were reported as the mean of three measurements at 25°C. The refractive index of the GO and water was set at 1.8 and 1.33, respectively. The surface properties of the drug functionalized nanocarrier were visualized using an AFM (MobileS, Nanosurf, Switzerland). The explorer AFM was in the noncontact mode, using high resonance frequency (F0170 kHz) pyramidal cantilevers with silicon probes having dynamic force. The diluted samples with the distilled water were dropped onto silicon plates and then vacuum dried for 24 hours at 25 °C.\n2.2.5. In vitro drug release study\nThe release profile of MTX from the drug loaded nanocarriers was studied using a dialysis tube (MWCO 12000 Da) at 37 ºC, in PBS pH 7.4. Briefly, about 6 mg of the MTX loaded nanocarrier was added to 2 mL of PBS. The acquired suspensions were spilled inside a dialysis membrane cylinder. The cylinder was then immersed in 100 mL PBS (pH 7.4). At predetermined\ntime intervals, 2 mL aliquots of the aqueous solution were withdrawn from the release media and another 2 mL fresh PBS was added into the release media. The amount of MTX released was monitored using a UV spectrophotometer at 302 nm.\n2.2.6. In vitro cytotoxicity study\nThe antiproliferative tests were carried out in accordance with a standard procedure [16]. The DA receptor positive human breast adenocarcinoma cell line (MCF7 cells) and DA receptor negative Human Embryonic Kidney 293 (HEK-293) cells were cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 °C and 5% CO2. Then the cells were placed in 96-well plates at a density of 10 4 cells per well in 100 µL of culture medium. Twenty-four hours later, various concentrations of the tested compounds (MTX, MTX loaded nGO, MTX loaded DA-nGO and unloaded DA-nGO) were added to the cells and incubated for 24 h. Unloaded DA-nGO has been selected as a negative control to study the cytotoxicity effect of the nanocarrier on the cell lines. The cytotoxic effect was measured using the MTT assay (MTT: 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide). The IC50 values (inhibitory concentration 50%) of MTX, MTX loaded nGO and MTX loaded DA-nGO for each cell line have been calculated separately."
    }, {
      "heading" : "2.2.7. Statistical analysis",
      "text" : "All data were presented as means ± standard deviation (SD). The results were analyzed using one-way analysis of variance (ANOVA), followed by post hoc LSD test for intergroup comparisons. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp. was used for statistical analysis, and p < 0.05 was regarded as statistically significant."
    }, {
      "heading" : "3. Results",
      "text" : ""
    }, {
      "heading" : "3.1. Characterization of synthesized drug loaded nanocarrier",
      "text" : "The steps for the synthesis of MTX loaded DA-nGO are shown in Figure 1. During nGO functionalization with DA, EDC was used as a cross linker which activates the carboxyl groups of nGO for the spontaneous reaction with the amino groups presented in the structure of DA. In order to confirm the efficiency of the conjugation process, the FTIR spectroscopy was used, the results are presented in Figure 2A. As the hydrochloride salt form of DA has been used in this experiment, the functionalization of nGO with DA resulted in the elimination of peaks related to amine hydrochloride of DA in the spectrum of DA-nGO such as 2436 cm -1 related to NH3 + in amine hydrochloride and 1500 cm -1 corresponding to NH3 + deformation in hydrohalide. The peak appearances of 3409 cm -1 related to N-H stretch and 1605 cm -1 corresponding to N-H bending in the spectrum of DA-nGO also confirm the amide bond formation between DA and nGO. After the DA-nGO production, it was treated with NaOH and Chloroacetic acid to obtain carboxylated DA-nGO, its FTIR spectra are illustrated in Figure 2A. Carboxylation of DA-nGO, resulted in elimination of some bonds at 3409 cm -1 corresponding to the O-H stretching bond in alcohols, 1250 cm -1 corresponding to C-O stretching in epoxides and 1068 cm -1 related to C-O stretching bond in cyclic alcohols. After MTX addition, the peak appearances of 3345 cm -1 corresponding to N-H stretch in primary amines and 1199 cm -1 related to C-N in aromatic amine in MTX-DA-nGO showed the absorbance of MTX on the surface of DA-nGO [17].\nThe morphology of the obtained materials was analyzed using FE-SEM and AFM. Figure 2B presents the SEM image of the starting nGO. The flakes are clearly apparent while the perception. The nGO material made of tenuous sheets closely related together to form an aggregated solid. The presence of a large number of oxygen-containing functional groups on the\nsurface of nGO nanosheets probably is the main factor of this accumulation. Figure 2C presents the MTX loaded DA-nGO. A comparison between Figure 2B and Figure 2C indicated that they are similar and the small discrimination observed between them can be explained by the difference in their surface shrinkage and roughness. It seems the surface of nGO showed no significant changes after conjugation with the drug.\nThe mean particle size and PDI of the nGO and MTX loaded DA-nGO were measured by photon correlation spectroscopy. As summarized in Table 1 the mean particle sizes of 255.7 nm and 342.7 nm were obtained for nGO and MTX loaded DA-nGO, respectively. The increase in size of MTX loaded DA-nGO in comparison with nGO must be due to loading of the drug and DA conjugation on surface of nGO. The PDI is a ratio providing information about the homogeneity of particle size distribution in a given system, and ideally, this should be 0.3 [18]. The PDI values of the nGO and MTX loaded DA-nGO were obtained 0.324 and 0.328, respectively, indicating the nanocarriers had a narrow size distribution, and suggesting nanocarrier monodispersity [18].\nThe topography and the height profiles of the constructed nanomaterials, which were analyzed with the AFM are illustrated in Figure 3. Here, the thickness of the nanomaterials indicated remarkable changes. GO demonstrates the thickness of about 5 nm. It is notable, the interlayer space of nGO has been estimated to be 0.85 nm, on the basis of Bragg’s law, and 0.8–1.2 nm thickness has been considered for a single-layer of graphene on a substrate of SiO2/Si [13, 19] Therefore, it is calculated that nGO is composed of approximately 5 layers. The thickness of nGO increased to about 10-20 nm after functionalization with DA, which showed the successful conjugation of DA on nGO. Furthermore, after DA-nGO conjugation with MTX, the thickness of nGO increased to about 40 nm, indicating successful drug deposition on the surface of DA-nGO.\n3.2. In vitro drug release\nMTX is one of the most potent anti-cancer drugs used in the treatment of different types of solid malignant tumors [13]. MTX was loaded on the surface of DA-nGO, and the unbound drugs were removed by centrifugation. To determine the actual drug loading content (DLC) and drug loading efficiency (DLE), the supernatant was analyzed using UV spectroscopy, wherein a calibration curve was obtained in PBS with different MTX concentrations. The results showed that the nanocarrier had DLC and DLE of 19.72 % and 81.88 %, respectively. In vitro drug release of the MTX loaded DA-nGO was evaluated in PBS, pH 7.4, at 37 ºC. As illustrated in Figure 4, the nanocarrier formulation showed an admissible drug release at pH 7.4 as approximately 80 % of the loaded MTX was released within the first 24 h.\nFurthermore, in order to realize the in vitro release kinetics of MTX from the DA-nGO, it is necessary to fit drug release data into a suitable model. Four most applied mathematical models were used to understand the release of MTX of DA-nGO i.e. the zero order, first order, Higuchi square root, and Korsmeyer–Peppas modeld. The release data acquired were treated according to zero-order (cumulative amount of drug released versus time), first order (log cumulative percentage of drug remaining versus time), Higuchi (cumulative percentage of release versus the square root of time) and Korsmeyer–Peppas (log cumulative percentage of drug released versus log time) equation models. Excel 2010 (Microsoft ® Corporation, Redmond, WA, USA) was used for the determination of the release rate constants (K) and the calculation of the correlation coefficients (R 2 ). It also was used for determination of the diffusional release exponent (n) that could be used to characterize the different release mechanisms [n ≤ 0.50 (Fickian diffusion), 0.50 < n < 1 (anomalous transport) and n = 1 (case II transport)]. As the best fitting model, the one with the highest correlation coefficient between the fitted data was selected of MTX from the\nDA-nGO showed a better fit with the Korsmeyer–Peppas model (See Table 2). Fitting the release data up to the Korsmeyer–Peppas equation and the amount of n value (0.469) suggested that release of MTX from the DA-nGO is through Fickian diffusion at pH 7.4 [18, 20, 21]. It occurs due to the diffusion of the dissolution medium into the DA-nGO. Since the pH of dissolution medium is more than pka of MTX, the medium can change the NH3 + groups of MTX to NH2 groups that can participate in the formation of hydrogen bonding with the carboxyl groups of nGO or hydroxyl groups of DA. In contrast the electrostatic repulsion between the negative groups of MTX and nGO triggers the release of drug from the nanocarrier. Therefore, through inducing a comparison between the absorption of MTX on the surface of DA-nGO and its release, the dissolution medium triggers the drug release slowly.\n3.3. In vitro Cytotoxicity test\nThe cytotoxicity of free MTX, MTX loaded nGO and MTX loaded DA-nGO were evaluated against the DA receptor positive MCF7 cells and DA receptor negative HEK-293 cells. In addition, the equivalent amounts of unloaded DA-nGO have been studied as control to investigate the toxicity effect of nanocarrier itself. The results indicated that unlike the control experiments that confirmed unloaded DA-nGO had no significant cytotoxicity against both MCF7 and HEK-293 cells (Figure 5a and 5a´), the cells treated with increasing concentrations of MTX, MTX loaded nGO and MTX loaded DA-nGO represented a dose-dependent decrease in viability for both cell lines (Figure 5b and 5b´). The IC50 values of free MTX, MTX loaded nGO and MTX loaded DA-nGO on MCF7 cells were 16.52 µg/mL, 18.8 µg/mL and 15.33 µg/mL, respectively. As deduced from the results were shown in Figure 5c, the IC50 of MTX loaded nGO on MCF7 cells showed significant difference with that of free MTX and MTX loaded DA-nGO, however there is no significant difference between the IC50 0f free MTX and\nMTX loaded DA-nGO. It may be related to the low uptake of MTX loaded nGO into the MCF7 cells in comparison with free MTX. While applying DA in designing nGO carrier for MTX could improve its cytotoxicity effect against MCF7 cells probably through higher uptake of nanocarrier via DA receptors on the cell surface. In the case of HEK-293 cells, the IC50 values of free MTX, MTX loaded nGO and MTX loaded DA-nGO were 73.18 µg/mL, 84.21 µg/mL and 83.73 µg/mL, respectively. As it shown in Figure 5c´, MTX loaded nGO and MTX loaded DA-nGO showed greater IC50 values for HEK-293 cells in comparison with free MTX. This results revealed that presence of DA on the surface of nanocarrier could not impress the cytotoxicity effect of the carrier on DA receptor negative cells. Therefore, it can be concluded that the presence of DA on the surface of nanocarrier helps to target the carrier to the DA receptor positive cells and it also can improve their entrance to the cells."
    }, {
      "heading" : "4. Discussion",
      "text" : "Overexpression of DA receptor in some cancer cells makes it a good candidate for its application in drug delivery systems. In the present study, we conjugated nGO with DA for delivery of MTX to the DA receptor positive cancer cells. As one derivative of graphene, nGO has a large number of caxboxyl functional groups which make it generally suitable for conjugation with the amino group of DA [22]. Due to its benzene ring and hydroxyl groups, DA can also bond to nGO via hydrophobic interaction and hydrogen bonding, respectively. To increase the functional groups which can provide hydrogen bonding with MTX, the surface of DA-nGO was carboxylated. However the carboxyl groups can accelerate the absorption of MTX on the surface of nanocarrier through hydrogen bonding, due to the negative charges of both DA-nGO and MTX at neutral pH, the drug loading should be carried out at the pH that is equal to pKa of MTX. Approximately, pka value of MTX is 4.7 and under this acidic condition, –NH2 of MTX forms –\nNH3 + and therefore can participate in electrostatic interaction with GO. Since the pKa distribution of GO is higher than 3.35, the GO sheets show negative charge, resulting in electrostatic interactions with MTX at acidic condition [11]. Moreover, the hydrophobic interaction between the basal plane of nGO and aromatic parts of MTX might be another force for the absorption of the drug on the surface of nanocarrier. After incubation of MTX loaded DA-nGO at neutral pH, the NH3 + groups of MTX were changed to NH2 and therefore the electrostatic interactions between NH3 + groups of MTX and COO - of nGO were decreased which accelerated the drug release at neutral pH conditions. The interaction of different types of graphene based materials with the mammalian cells has been investigated in several studies and it was indicated that graphene and graphene-related nanomaterials are primarily internalized into cells via endocytosis, then some studies have shown that the internalization of graphene is a mechanism that can lead to cell intoxication, while other studies have shown that graphene internalization can transport therapeutic agents intracellularly without ensuing damage [23]. In the case of MCF7, the endosytosis of drug loaded GO into MCF7 cell line has been confirmed in the research of Tran et al. [24]. In another study Saeed et al. investigated the endocytosis of drug loaded graphene in to the MCF7 cell line [25]. In the case of HEK293, Gurunathan et al. observed the state of oxidative stress in this cell line following its exposure to high concentration of GO. They concluded that this GO-mediated cell death is caused by increased intracellular ROS levels originating from mitochondrial damage [26]. In another study by Chen et al. fluorescence imaging confirmed the minimal non-specific interaction and uptake of graphene based material into the HEK-293 cells [27]. In this study, DA receptor positive MCF7 cells and DA receptor negative HEK-293 cells have been used to investigate the targeting effect of DA for delivery of MTX loaded nGO to the cancerous cells overexpressing DA receptors. The\ncomparison between the cytotoxicity and IC50 of MTX loaded nGO with MTX loaded DA-nGO on MCF7 cell viability demonstrated that the presence of DA also had a significant effect on uptake of drug loaded nanocarriers into the MCF7 cells. In the case of HEK-293, using nanocarriers for delivery of MTX could not improve its toxicity against cells and also the presence of DA did not show significant effect on cell viability in comparison with MTX loaded nGO. These results are in agreement with the findings of Das and Jana that designed a DA functionalized polymeric nanoparticle for cellular delivery of the drug into human colon adenocarcinoma cells. They applied DA receptor positive human colon adenocarcinoma HT-29 cells and DA receptors negative normal mouse embryonic fibroblasts 3T3-L1 cells. The results of their study could be explained by enhanced drug uptake by DA receptors positive HT-29 cells as compared to low drug uptake by DA receptors negative 3T3-L1 cells [8]. Therefore, it could be concluded that using DA for targeted drug delivery can improve the uptake of drug loaded nanocarriers just in DA receptor positive cell lines and do not show significant impact on DA receptor negative cells."
    }, {
      "heading" : "5. Conclusion",
      "text" : "In summary, we have synthesized DA functionalized nGO nanocarrier to deliver MTX to the cells processing DA receptors. In vitro release study showed that the extended release characteristic of MTX was well fitted to Korsmeyer-Peppas model, implying that the release profile of MTX from DA-nGO is diffusion-controlled. In vitro cytotoxicity tests demonstrated that the presence of DA on the surface of nanocarrier helps to target the carrier to the DA receptor positive cells and can improve their entrance into the cells.\n6. References\n[1] P. Debbage, Targeted drugs and nanomedicine: present and future, Current pharmaceutical design, 15 (2009) 153-172. [2] X.-J. Liang, C. Chen, Y. Zhao, P.C. Wang, Circumventing tumor resistance to chemotherapy by nanotechnology, Multi-Drug Resistance in Cancer, (2010) 467-488. [3] X. Zhao, H. Li, R.J. Lee, Targeted drug delivery via folate receptors, Expert opinion on drug delivery, 5 (2008) 309-319. [4] K. Cho, X. Wang, S. Nie, D.M. Shin, Therapeutic nanoparticles for drug delivery in cancer, Clinical cancer research, 14 (2008) 1310-1316. [5] Y.H. Bae, K. Park, Targeted drug delivery to tumors: myths, reality and possibility, Journal of Controlled Release, 153 (2011) 198. [6] S.P. Vyas, A. Singh, V. Sihorkar, Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting, Critical Reviews™ in Therapeutic Drug Carrier Systems, 18 (2001). [7] D. Borcherding, W. Tong, E. Hugo, D. Barnard, S. Fox, K. LaSance, E. Shaughnessy, N. Ben-Jonathan, Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer, Oncogene, (2015). [8] P. Das, N.R. Jana, Dopamine functionalized polymeric nanoparticle for targeted drug delivery, RSC Advances, 5 (2015) 33586-33594. [9] J.L. Cadet, S. Jayanthi, M.T. McCoy, G. Beauvais, N.S. Cai, Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration, CNS & neurological disorders drug targets, 9 (2010) 526. [10] D. Chakroborty, C. Sarkar, H. Yu, J. Wang, Z. Liu, P.S. Dasgupta, S. Basu, Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cells, Proceedings of the National Academy of Sciences, 108 (2011) 20730-20735. [11] L. Du, S. Suo, D. Luo, H. Jia, Y. Sha, Y. Liu, Hydroxyethylated graphene oxide as potential carriers for methotrexate delivery, Journal of nanoparticle research, 15 (2013) 1-7. [12] P. Huang, S. Wang, X. Wang, G. Shen, J. Lin, Z. Wang, S. Guo, D. Cui, M. Yang, X. Chen, Surface Functionalization of Chemically Reduced Graphene Oxide for Targeted Photodynamic Therapy, Journal of biomedical nanotechnology, 11 (2015) 117-125. [13] M. Wojtoniszak, K. Urbas, M. Perużyńska, M. Kurzawski, M. Droździk, E. Mijowska, Covalent conjugation of graphene oxide with methotrexate and its antitumor activity, Chemical Physics Letters, 568 (2013) 151-156. [14] W.S. Hummers Jr, R.E. Offeman, Preparation of graphitic oxide, Journal of the American Chemical Society, 80 (1958) 1339-1339. [15] X. Sun, Z. Liu, K. Welsher, J.T. Robinson, A. Goodwin, S. Zaric, H. Dai, Nano-graphene oxide for cellular imaging and drug delivery, Nano research, 1 (2008) 203-212. [16] S. Vijayakumar, S. Ganesan, In vitro cytotoxicity assay on gold nanoparticles with different stabilizing agents, Journal of Nanomaterials, 2012 (2012) 14. [17] J.B. Lambert, Introduction to organic spectroscopy, 1987. [18] A. hemati Azandaryani, K. Derakhshandeh, New surface-modified solid lipid nanoparticles using Nglutaryl phosphatidylethanolamine as the outer shell, International journal of nanomedicine, 6 (2011) 2393-2401. [19] M. Wojtoniszak, E. Mijowska, Controlled oxidation of graphite to graphene oxide with novel oxidants in a bulk scale, Journal of Nanoparticle Research, 14 (2012) 1-7. [20] H. Pandey, V. Parashar, R. Parashar, R. Prakash, P.W. Ramteke, A.C. Pandey, Controlled drug release characteristics and enhanced antibacterial effect of graphene nanosheets containing gentamicin sulfate, Nanoscale, 3 (2011) 4104-4108. [21] S. Kashanian, E. Rostami, PEG-stearate coated solid lipid nanoparticles as levothyroxine carriers for oral administration, Journal of nanoparticle research, 16 (2014) 1-10.\n[22] R.K. Layek, A.K. Nandi, A review on synthesis and properties of polymer functionalized graphene, Polymer, 54 (2013) 5087-5103. [23] B. Zhang, P. Wei, Z. Zhou, T. Wei, Interactions of graphene with mammalian cells: Molecular mechanisms and biomedical insights, Advanced Drug Delivery Reviews, 105 (2016) 145-162. [24] T.H. Tran, H.T. Nguyen, T.T. Pham, J.Y. Choi, H.-G. Choi, C.S. Yong, J.O. Kim, Development of a graphene oxide nanocarrier for dual-drug chemo-phototherapy to overcome drug resistance in cancer, ACS applied materials & interfaces, 7 (2015) 28647-28655. [25] L.M. Saeed, M. Mahmood, S.J. Pyrek, T. Fahmi, Y. Xu, T. Mustafa, Z.A. Nima, S.M. Bratton, D. Casciano, E. Dervishi, Single‐walled carbon nanotube and graphene nanodelivery of gambogic acid increases its cytotoxicity in breast and pancreatic cancer cells, Journal of Applied Toxicology, 34 (2014) 1188-1199. [26] S. Gurunathan, J.W. Han, E. Kim, D.-N. Kwon, J.-K. Park, J.-H. Kim, Enhanced green fluorescent protein-mediated synthesis of biocompatible graphene, Journal of nanobiotechnology, 12 (2014) 1. [27] M.-L. Chen, Y.-J. He, X.-W. Chen, J.-H. Wang, Quantum-dot-conjugated graphene as a probe for simultaneous cancer-targeted fluorescent imaging, tracking, and monitoring drug delivery, Bioconjugate chemistry, 24 (2013) 387-397."
    }, {
      "heading" : "Table legend",
      "text" : "Table 1. Particle size and PDI of synthesized nanocarriers. Table 2. Release rate constant Ks and correlation coefficient (R 2 ) calculated after fitting the release profile obtained using different mathematical models."
    }, {
      "heading" : "Figure legends",
      "text" : "Figure 1. The modification of nGO (a), for production of DA-nGO (b), Carboxylated nGO (c) and MTX loaded DA-nGO (d). Figure 2. A) FT-IR spectra of nGO (a), DA (b), DA-nGO (c), Carboxylated DA-nGO (d), MTX (e) and MTX loaded DA-nGO (f); B) The SEM image of nGO; C) The SEM image of MTX loaded DA-nGO. Figure 3. The AFM images of nGO (a), DA-nGO (b), MTX loaded DA-nGO (c) and the height profiles of nGO (a´), DA-nGO (b´) and MTX loaded DA-nGO (c´). Figure 4. Percentages of the cumulative release of MTX from MTX loaded DA-nGO at pH 7.4 (Means ± SD, n = 3). Figure 5. The effect of different concentrations of unloaded DA-nGO against MCF7 cell viability (a) and HEK-239 cell viability (a´), the effect of different concentrations of free MTX, MTX loaded nGO and MTX loaded DA-nGO against MCF7 cells viability (b) and HEK-239 cell viability (b´), the IC50 values of MTX, MTX loaded nGO and MTX loaded DA-nGO on MCF7 cells (c) and HEK-293 cells (c´), (Means ± SD, n = 3, P<0.05, * Stands for no significant difference).\nFormulation Zero Order First Order Korsmeyer-Peppas Higuchi\nMTX loaded\nDA-nGO\nK0 R 2 K1 R 2 n R 2 KH R\n1.749 ±.044 0.702 0.29 ± 0 0.762 0.469 ± 0.071 0.919 14.98 ± 0.326 0.951\nNotes: Each value stands for the mean of three experiments ± SD.\nFigure 5"
    }, {
      "heading" : "A Targeted Drug Delivery System Based on Dopamine Functionalized Nano",
      "text" : ""
    }, {
      "heading" : "Graphene Oxide",
      "text" : "Elham Masoudipour, Soheila Kashanian  , Nasim Maleki"
    }, {
      "heading" : "Highlights",
      "text" : " Dopamine receptors can be employed for specific targeting of cancer cells.  Presence of dopamine on the surface of methotrexate loaded nano graphene oxide\nimproves the cytotoxic effect of drug on a dopamine receptor positive cell line.\n The release profile of methotrexate from dopamine conjugated nano graphene oxide is\ndiffusion-controlled."
    } ],
    "references" : [ {
      "title" : "Targeted drugs and nanomedicine: present and future",
      "author" : [ "P. Debbage" ],
      "venue" : "Current pharmaceutical design, 15 ",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Circumventing tumor resistance to chemotherapy by nanotechnology",
      "author" : [ "X.-J. Liang", "C. Chen", "Y. Zhao", "P.C. Wang" ],
      "venue" : "Multi-Drug Resistance in Cancer, ",
      "citeRegEx" : "2",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Targeted drug delivery via folate receptors",
      "author" : [ "X. Zhao", "H. Li", "R.J. Lee" ],
      "venue" : "Expert opinion on drug delivery, 5 ",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Therapeutic nanoparticles for drug delivery in cancer",
      "author" : [ "K. Cho", "X. Wang", "S. Nie", "D.M. Shin" ],
      "venue" : "Clinical cancer research, 14 ",
      "citeRegEx" : "4",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Targeted drug delivery to tumors: myths",
      "author" : [ "Y.H. Bae", "K. Park" ],
      "venue" : "reality and possibility, Journal of Controlled Release, 153 ",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting",
      "author" : [ "S.P. Vyas", "A. Singh", "V. Sihorkar" ],
      "venue" : "Critical ReviewsTM in Therapeutic Drug Carrier Systems, 18 ",
      "citeRegEx" : "6",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer",
      "author" : [ "D. Borcherding", "W. Tong", "E. Hugo", "D. Barnard", "S. Fox", "K. LaSance", "E. Shaughnessy", "N. Ben-Jonathan" ],
      "venue" : "Oncogene, ",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Dopamine functionalized polymeric nanoparticle for targeted drug delivery",
      "author" : [ "P. Das", "N.R. Jana" ],
      "venue" : "RSC Advances, 5 ",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Dopamine D1 receptors",
      "author" : [ "J.L. Cadet", "S. Jayanthi", "M.T. McCoy", "G. Beauvais", "N.S. Cai" ],
      "venue" : "regulation of gene expression in the brain, and neurodegeneration, CNS & neurological disorders drug targets, 9 ",
      "citeRegEx" : "9",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cells",
      "author" : [ "D. Chakroborty", "C. Sarkar", "H. Yu", "J. Wang", "Z. Liu", "P.S. Dasgupta", "S. Basu" ],
      "venue" : "Proceedings of the National Academy of Sciences, 108 ",
      "citeRegEx" : "10",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Hydroxyethylated graphene oxide as potential carriers for methotrexate delivery",
      "author" : [ "L. Du", "S. Suo", "D. Luo", "H. Jia", "Y. Sha", "Y. Liu" ],
      "venue" : "Journal of nanoparticle research, 15 ",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Surface Functionalization of Chemically Reduced Graphene Oxide for Targeted Photodynamic Therapy",
      "author" : [ "P. Huang", "S. Wang", "X. Wang", "G. Shen", "J. Lin", "Z. Wang", "S. Guo", "D. Cui", "M. Yang", "X. Chen" ],
      "venue" : "Journal of biomedical nanotechnology, 11 ",
      "citeRegEx" : "12",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Covalent conjugation of graphene oxide with methotrexate and its antitumor activity",
      "author" : [ "M. Wojtoniszak", "K. Urbas", "M. Perużyńska", "M. Kurzawski", "M. Droździk", "E. Mijowska" ],
      "venue" : "Chemical Physics Letters, 568 ",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Preparation of graphitic oxide",
      "author" : [ "W.S. Hummers Jr", "R.E. Offeman" ],
      "venue" : "Journal of the American Chemical Society, 80 ",
      "citeRegEx" : "14",
      "shortCiteRegEx" : null,
      "year" : 1958
    }, {
      "title" : "Nano-graphene oxide for cellular imaging and drug delivery",
      "author" : [ "X. Sun", "Z. Liu", "K. Welsher", "J.T. Robinson", "A. Goodwin", "S. Zaric", "H. Dai" ],
      "venue" : "Nano research, 1 ",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "In vitro cytotoxicity assay on gold nanoparticles with different stabilizing agents",
      "author" : [ "S. Vijayakumar", "S. Ganesan" ],
      "venue" : "Journal of Nanomaterials, 2012 ",
      "citeRegEx" : "16",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "New surface-modified solid lipid nanoparticles using Nglutaryl phosphatidylethanolamine as the outer shell",
      "author" : [ "A. hemati Azandaryani", "K. Derakhshandeh" ],
      "venue" : "International journal of nanomedicine,",
      "citeRegEx" : "18",
      "shortCiteRegEx" : "18",
      "year" : 2011
    }, {
      "title" : "Controlled oxidation of graphite to graphene oxide with novel oxidants in a bulk scale",
      "author" : [ "M. Wojtoniszak", "E. Mijowska" ],
      "venue" : "Journal of Nanoparticle Research, 14 ",
      "citeRegEx" : "19",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Controlled drug release characteristics and enhanced antibacterial effect of graphene nanosheets containing gentamicin sulfate",
      "author" : [ "H. Pandey", "V. Parashar", "R. Parashar", "R. Prakash", "P.W. Ramteke", "A.C. Pandey" ],
      "venue" : "Nanoscale, 3 ",
      "citeRegEx" : "20",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "PEG-stearate coated solid lipid nanoparticles as levothyroxine carriers for oral administration",
      "author" : [ "S. Kashanian", "E. Rostami" ],
      "venue" : "Journal of nanoparticle research, 16 ",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "A review on synthesis and properties of polymer functionalized graphene",
      "author" : [ "R.K. Layek", "A.K. Nandi" ],
      "venue" : "Polymer, 54 ",
      "citeRegEx" : "22",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Interactions of graphene with mammalian cells: Molecular mechanisms and biomedical insights",
      "author" : [ "B. Zhang", "P. Wei", "Z. Zhou", "T. Wei" ],
      "venue" : "Advanced Drug Delivery Reviews, 105 ",
      "citeRegEx" : "23",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Development of a graphene oxide nanocarrier for dual-drug chemo-phototherapy to overcome drug resistance in cancer",
      "author" : [ "T.H. Tran", "H.T. Nguyen", "T.T. Pham", "J.Y. Choi", "H.-G. Choi", "C.S. Yong", "J.O. Kim" ],
      "venue" : "ACS applied materials & interfaces, 7 ",
      "citeRegEx" : "24",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Single‐walled carbon nanotube and graphene nanodelivery of gambogic acid increases its cytotoxicity in breast and pancreatic cancer cells",
      "author" : [ "L.M. Saeed", "M. Mahmood", "S.J. Pyrek", "T. Fahmi", "Y. Xu", "T. Mustafa", "Z.A. Nima", "S.M. Bratton", "D. Casciano", "E. Dervishi" ],
      "venue" : "Journal of Applied Toxicology, 34 ",
      "citeRegEx" : "25",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Enhanced green fluorescent protein-mediated synthesis of biocompatible graphene",
      "author" : [ "S. Gurunathan", "J.W. Han", "E. Kim", "D.-N. Kwon", "J.-K. Park", "J.-H. Kim" ],
      "venue" : "Journal of nanobiotechnology, 12 ",
      "citeRegEx" : "26",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Quantum-dot-conjugated graphene as a probe for simultaneous cancer-targeted fluorescent imaging",
      "author" : [ "M.-L. Chen", "Y.-J. He", "X.-W. Chen", "J.-H. Wang" ],
      "venue" : "tracking, and monitoring drug delivery, Bioconjugate chemistry, 24 ",
      "citeRegEx" : "27",
      "shortCiteRegEx" : null,
      "year" : 2013
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "compatibility and safety of therapeutic agents [1].",
      "startOffset" : 47,
      "endOffset" : 50
    }, {
      "referenceID" : 1,
      "context" : "This may help to solve the problems associated with cancer treatment to reduce the dose-limiting cytotoxicity of the drug and also can enable the drug to bypass the drug resistance [2, 3].",
      "startOffset" : 181,
      "endOffset" : 187
    }, {
      "referenceID" : 2,
      "context" : "This may help to solve the problems associated with cancer treatment to reduce the dose-limiting cytotoxicity of the drug and also can enable the drug to bypass the drug resistance [2, 3].",
      "startOffset" : 181,
      "endOffset" : 187
    }, {
      "referenceID" : 3,
      "context" : "Nanocarriers can increase the intracellular concentration of drugs in cancer cells using both passive and active targeting strategies, while preventing toxicity in normal cells [4].",
      "startOffset" : 177,
      "endOffset" : 180
    }, {
      "referenceID" : 3,
      "context" : "Nanocarriers can be conjugated with different targeting ligands to bind to cancer specific receptors and then enter the cell via receptor-mediated endocytosis and thereby bypassing drug resistance mechanisms [4, 5].",
      "startOffset" : 208,
      "endOffset" : 214
    }, {
      "referenceID" : 4,
      "context" : "Nanocarriers can be conjugated with different targeting ligands to bind to cancer specific receptors and then enter the cell via receptor-mediated endocytosis and thereby bypassing drug resistance mechanisms [4, 5].",
      "startOffset" : 208,
      "endOffset" : 214
    }, {
      "referenceID" : 5,
      "context" : "To date, several ligand-receptor systems have been studied for targeted drug delivery such as lectin receptors, Fc receptors, complement receptors, interleukin receptors, lipoprotein receptors, transferrin receptors and receptors expressed on tumor cells [6].",
      "startOffset" : 255,
      "endOffset" : 258
    }, {
      "referenceID" : 6,
      "context" : "Dopamine (DA) receptors are examples of these receptors that are overexpressed in some cancer cells, such as human colon adenocarcinoma cells and breast cancer cells [7, 8].",
      "startOffset" : 166,
      "endOffset" : 172
    }, {
      "referenceID" : 7,
      "context" : "Dopamine (DA) receptors are examples of these receptors that are overexpressed in some cancer cells, such as human colon adenocarcinoma cells and breast cancer cells [7, 8].",
      "startOffset" : 166,
      "endOffset" : 172
    }, {
      "referenceID" : 8,
      "context" : "its D1 and D2 class of receptors and has a significant function in central nervous system of brain [9].",
      "startOffset" : 99,
      "endOffset" : 102
    }, {
      "referenceID" : 7,
      "context" : "Das and Jana investigated that DA functionalized polymeric nanoparticle can selectively deliver anticancer drugs curcumin, camptothecin and doxorubicin to human colon adenocarcinoma cells and expected to be an alternative drug delivery carrier for in vitro and in vivo applications [8].",
      "startOffset" : 282,
      "endOffset" : 285
    }, {
      "referenceID" : 9,
      "context" : "4 prostate cancers, to indicate that DA can increase blood flow and improve the efficiency of anticancer drug delivery to the tumors [10].",
      "startOffset" : 133,
      "endOffset" : 137
    }, {
      "referenceID" : 10,
      "context" : "Due to one-atom thickness and two-dimensional plane, GO can provide a large specific surface area for the immobilization of a large number of drugs [11].",
      "startOffset" : 148,
      "endOffset" : 152
    }, {
      "referenceID" : 11,
      "context" : "It improves their aqueous dispersibility, reduce aggregation of nanosheets, decrease the toxicity, and increase its selectivity [12].",
      "startOffset" : 128,
      "endOffset" : 132
    }, {
      "referenceID" : 2,
      "context" : "carboxylated GO conjugated folate-terminated PEG (CG–PEG–FA) nanocarrier which demonstrated lasting dispersibility in PBS media, excellent cytocompatibility, high drug-loading efficiency, and perfect targeting to folate receptor [3].",
      "startOffset" : 229,
      "endOffset" : 232
    }, {
      "referenceID" : 12,
      "context" : "MTX is a folic acid analog used as a chemotherapeutic agent, widely applied in the treatment of a wide range of cancers, rheumatoid arthritis, and other diseases [13].",
      "startOffset" : 162,
      "endOffset" : 166
    }, {
      "referenceID" : 13,
      "context" : "GO was synthesized following the Modified Hummer’s method [14].",
      "startOffset" : 58,
      "endOffset" : 62
    }, {
      "referenceID" : 14,
      "context" : "2 g) were added to the aqueous dispersion of DAnGO (2 mg/mL) and sonicated for 3 h to alter –OH and epoxide groups to –COOH groups by the attachment of –CH2COOH linker [15].",
      "startOffset" : 168,
      "endOffset" : 172
    }, {
      "referenceID" : 15,
      "context" : "The antiproliferative tests were carried out in accordance with a standard procedure [16].",
      "startOffset" : 85,
      "endOffset" : 89
    }, {
      "referenceID" : 16,
      "context" : "328, respectively, indicating the nanocarriers had a narrow size distribution, and suggesting nanocarrier monodispersity [18].",
      "startOffset" : 121,
      "endOffset" : 125
    }, {
      "referenceID" : 12,
      "context" : "2 nm thickness has been considered for a single-layer of graphene on a substrate of SiO2/Si [13, 19] Therefore, it is calculated that nGO is composed of approximately 5 layers.",
      "startOffset" : 92,
      "endOffset" : 100
    }, {
      "referenceID" : 17,
      "context" : "2 nm thickness has been considered for a single-layer of graphene on a substrate of SiO2/Si [13, 19] Therefore, it is calculated that nGO is composed of approximately 5 layers.",
      "startOffset" : 92,
      "endOffset" : 100
    }, {
      "referenceID" : 20,
      "context" : "As one derivative of graphene, nGO has a large number of caxboxyl functional groups which make it generally suitable for conjugation with the amino group of DA [22].",
      "startOffset" : 160,
      "endOffset" : 164
    }, {
      "referenceID" : 10,
      "context" : "electrostatic interactions with MTX at acidic condition [11].",
      "startOffset" : 56,
      "endOffset" : 60
    }, {
      "referenceID" : 21,
      "context" : "graphene based materials with the mammalian cells has been investigated in several studies and it was indicated that graphene and graphene-related nanomaterials are primarily internalized into cells via endocytosis, then some studies have shown that the internalization of graphene is a mechanism that can lead to cell intoxication, while other studies have shown that graphene internalization can transport therapeutic agents intracellularly without ensuing damage [23].",
      "startOffset" : 466,
      "endOffset" : 470
    }, {
      "referenceID" : 23,
      "context" : "investigated the endocytosis of drug loaded graphene in to the MCF7 cell line [25].",
      "startOffset" : 78,
      "endOffset" : 82
    }, {
      "referenceID" : 24,
      "context" : "They concluded that this GO-mediated cell death is caused by increased intracellular ROS levels originating from mitochondrial damage [26].",
      "startOffset" : 134,
      "endOffset" : 138
    }, {
      "referenceID" : 25,
      "context" : "fluorescence imaging confirmed the minimal non-specific interaction and uptake of graphene based material into the HEK-293 cells [27].",
      "startOffset" : 129,
      "endOffset" : 133
    }, {
      "referenceID" : 7,
      "context" : "The results of their study could be explained by enhanced drug uptake by DA receptors positive HT-29 cells as compared to low drug uptake by DA receptors negative 3T3-L1 cells [8].",
      "startOffset" : 176,
      "endOffset" : 179
    } ],
    "year" : 2016,
    "abstractText" : null,
    "creator" : "Elsevier"
  }
}